Nymox Pharmaceutical Corporation provided a further update its ongoing Phase 3 trials (NX02-0017 and NX02-0018) for NX-1207, Nymox’s investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting found no significant safety concerns to date for the two pivotal U.S. trials being conducted at over 70 urology clinical research sites across the U.S.

Completed Phase 2 studies have shown that a single administration of NX-1207 resulted in symptomatic improvements which reached statistical significance compared to double-blinded placebo and study controls.

Patient-reported improvements in the standardized BPH symptom score were on average 8 to 10 points at 90 days as compared to the approximately 3 to 5 points reported on average for currently approved BPH drugs. The drug is administered by a urologist in an office setting in a brief procedure that does not require anesthesia, sedation, or catheterization and involves little or no pain or discomfort. NX-1207 treatment has not been found to have the sexual, blood pressure, or other side effects associated with the use of the approved drugs for the treatment of BPH. Follow-up studies have shown clinical efficacy effects lasting up to 7 years after a single treatment.

Date: May 3, 2011
Source: Nymox Pharmaceutical Corporation